BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18495222)

  • 1. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
    Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
    Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
    Bian J; Sun X; Li B; Ming L
    Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
    Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
    Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
    Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
    Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
    Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
    BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
    Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
    J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.
    Huhtinen K; Suvitie P; Hiissa J; Junnila J; Huvila J; Kujari H; Setälä M; Härkki P; Jalkanen J; Fraser J; Mäkinen J; Auranen A; Poutanen M; Perheentupa A
    Br J Cancer; 2009 Apr; 100(8):1315-9. PubMed ID: 19337252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
    Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
    Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
    Lowe KA; Shah C; Wallace E; Anderson G; Paley P; McIntosh M; Andersen MR; Scholler N; Bergan L; Thorpe J; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2480-7. PubMed ID: 18768519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
    Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.
    Angioli R; Plotti F; Capriglione S; Montera R; Damiani P; Ricciardi R; Aloisi A; Luvero D; Cafà EV; Dugo N; Angelucci M; Benedetti-Panici P
    Tumour Biol; 2013 Feb; 34(1):571-6. PubMed ID: 23179397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma].
    Zhang AM; Zhang P
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):125-8. PubMed ID: 22455745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
    Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
    Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
    Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.
    Abdalla N; Pazura M; Słomka A; Piórkowski R; Sawicki W; Cendrowski K
    Ginekol Pol; 2016; 87(12):781-786. PubMed ID: 28098927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.